medigraphic.com
Órgano Oficial de la Asociación Mexicana de Infectología Pediátrica y la SLIPE.

2013, Number 106

<< Back

Rev Enfer Infec Pediatr 2013; 26.27 (106)

Vaccines: Meningococcal Disease

Hernández PM, González SN

Language: Spanish
References: 57
Page: 389--393
PDF size: 259.15 Kb.


ABSTRACT

Meningococcal disease is a serious clinical condition of the patient leading to devastating results, with high public health impact. Neisseria meningitidis (meningococcus) is a Gram-negative diplococcus with at least 12 capsular serologically distinct groups (serogroups). In Latin America the incidence of the disease varies in Mexico yet officially reported about 80 cases per year, the largest number of cases are concentrated in children under 5 years, especially in the 1 year old. In Mexico there’re meningococcal conjugate vaccine and quadrivalent conjugate meningococcal vaccine. Children should be vaccinated before one year of age with two or three doses of pneumococcal conjugate vaccine, with this background can be applied meningococcal conjugate vaccine. In children aged 2-6 years should be given a booster every three years after the initial vaccination in case of attending to risk areas, because the concentrations of bactericidal antibodies against serogroups contained in the vaccine after this time will decrease. For adolescents aged 11 or 12 years, with a booster dose at age 16 years. ACIP.


REFERENCES

  1. López E, Debbag R. Enfermedad meningocócoca: siempre presente. Cambios en los serogrupos en el Cono Sur. Rev. Chil. Inf. 2012; 29: S87.

  2. American Academic of Pediatrics. Infecciones meningocócicas. En: Pickering LK, Baker CJ, Kimberlin DW, Long MD eds. Red book: Informe 2012 del Comité de Enfermedades infecciosas. Elk Grove Village, IL: American Academy of Pediatrics 2012:500-9.

  3. Granoff DM, Pelton S, Harrison LH. Meningococcal vaccines in: PlotkinSA, Orenstein WA, Offit PA ed. Vaccines 6th ed. Elsevier Saunders. China 2013; 388-418.

  4. Knapp JS, Koumans EH. Neisseria and Branhamella. In: Murray PR, Baron Ej, Jorgensen JH et al ed. Manual of Clinical Microbiology, 9th ed. Washington, DC: ASM Press. 2007; 586-603.

  5. Branham SE. Serological relationships among meningococci. Bacteriol Rev. 1953 Sep; 17(3): 175-88.

  6. Vedros NA. Development of meningococcal serogrups. In Vedros NA. Ed.Evolution of Meningococcal Disease, Boca Raton, FL: CRC Press. 1987; 33-37.

  7. Safadi MAP, Sáenz-Llorens X, Gonzalez-Ayala S, et al. Efforts to control and prevented meningococcal disease in Latin America. The Global Meningococcal Initiative WSPID. 2011.

  8. Safadi MA, Cintra OA. Epidemiology of meningococal disease in Latin America: Current Situation and opportunities for prevention, Neurological Research. 2010; 32(3): 263-264.

  9. López EL, Debbag R. Enfermedad meningocócica: siempre presente. Cambios en los serogrupos en el Cono Sur. Rev Chilena Infectol. 2012; 29(6): 587-94.

  10. SS. Información Epidemiológica de Morbilidad, Anuario 2009, pp.118.6. Dirección General de Epidemiología 2009.

  11. Vigilancia Epidemiológica semana 26-2013. SS (México).

  12. Espinosa LE, Aguilar-Ituarte F, Jiménez-Rojas LV, et al. Prevalence of Neisseria meningitidis carriers in children under five years of age and teenagers in certain populations of Mexico City. Salud Pública de México. 2009 Mar-abr; 51(2): 114-8.

  13. Espinosa de los Monteros LE, Jiménez LV, Villaseñor I, et al. Prevalence of N. meningitidis carriers in two prisons in Mexico during the epidemiological emergency of a meningitid outbreak in Mexico City (2010). 2012.

  14. Centers for Disease Control and Prevention (CDC) Prevention and Control of Meningococcal Disease Recommendations of Advisory Committee on Immunization Practices (ACIP) MMWR 2005; 54(No. RR-7): 1-21.

  15. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedules for Persons Aged 0 through 18 years and adults aged 19 years and older - United States, 2013 MMWR. 2013; 62(Suppl1): 1-19.

  16. Nassif X. Interaction mechanisms of encapsulated meningococci with eucaryotic cells: what does this tell us about the crossing of the blood-brain barrier by Neisseria meningitidis?. CurrOpin Microbiol. 1999 Feb; 2(1): 71-7.

  17. Red Book online update 7-septiembre 2013 (Chapter meningococcal infectious).

  18. MMWR. 2013; 62: 2.

  19. Harrison O.B. y Cols Description and Nomenclature of Neisseria meningitidis Capsule locus. Emerg. Infec. Dis. 2013: 19(4); 566.

  20. López E, Debbag R. Enfermedad meningocócoca: siempre presente. Cambios en los serogrupos en el Cono Sur. Rev. Chil. Inf. 2012; 29: S87.

  21. American Academic of Pediatrics. Infecciones meningocócicas. En: Pickering LK, Baker CJ, Kimberlin DW, Long MD eds. Red book: Informe 2012 del Comité de Enfermedades infecciosas. Elk Grove Village, IL: American Academy of Pediatrics 2012:500-9.

  22. Granoff DM, Pelton S, Harrison LH. Meningococcal vaccines in: PlotkinSA, Orenstein WA, Offit PA ed. Vaccines 6th ed. Elsevier Saunders. China 2013; 388-418.

  23. Knapp JS, Koumans EH. Neisseria and Branhamella. In: Murray PR, Baron Ej, Jorgensen JH et al ed. Manual of Clinical Microbiology, 9th ed. Washington, DC: ASM Press. 2007; 586-603.

  24. Branham SE. Serological relationships among meningococci. Bacteriol Rev. 1953 Sep; 17(3): 175-88.

  25. Vedros NA. Development of meningococcal serogrups. In Vedros NA. Ed.Evolution of Meningococcal Disease, Boca Raton, FL: CRC Press. 1987; 33-37.

  26. Safadi MAP, Sáenz-Llorens X, Gonzalez-Ayala S, et al. Efforts to control and prevented meningococcal disease in Latin America. The Global Meningococcal Initiative WSPID. 2011.

  27. Safadi MA, Cintra OA. Epidemiology of meningococal disease in Latin America: Current Situation and opportunities for prevention, Neurological Research. 2010; 32(3): 263-264.

  28. López EL, Debbag R. Enfermedad meningocócica: siempre presente. Cambios en los serogrupos en el Cono Sur. Rev Chilena Infectol. 2012; 29(6): 587-94.

  29. SS. Información Epidemiológica de Morbilidad, Anuario 2009, pp.118.6. Dirección General de Epidemiología 2009.

  30. Vigilancia Epidemiológica semana 26-2013. SS (México).

  31. Espinosa LE, Aguilar-Ituarte F, Jiménez-Rojas LV, et al. Prevalence of Neisseria meningitidis carriers in children under five years of age and teenagers in certain populations of Mexico City. Salud Pública de México. 2009 Mar-abr; 51(2): 114-8.

  32. Espinosa de los Monteros LE, Jiménez LV, Villaseñor I, et al. Prevalence of N. meningitidis carriers in two prisons in Mexico during the epidemiological emergency of a meningitid outbreak in Mexico City (2010). 2012.

  33. Centers for Disease Control and Prevention (CDC) Prevention and Control of Meningococcal Disease Recommendations of Advisory Committee on Immunization Practices (ACIP) MMWR 2005; 54(No. RR-7): 1-21.

  34. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedules for Persons Aged 0 through 18 years and adults aged 19 years and older - United States, 2013 MMWR. 2013; 62(Suppl1): 1-19.

  35. Nassif X. Interaction mechanisms of encapsulated meningococci with eucaryotic cells: what does this tell us about the crossing of the blood-brain barrier by Neisseria meningitidis?. CurrOpin Microbiol. 1999 Feb; 2(1): 71-7.

  36. Red Book online update 7-septiembre 2013 (Chapter meningococcal infectious).

  37. MMWR. 2013; 62: 2.

  38. Harrison O.B. y Cols Description and Nomenclature of Neisseria meningitidis Capsule locus. Emerg. Infec. Dis. 2013: 19(4); 566.

  39. López E, Debbag R. Enfermedad meningocócoca: siempre presente. Cambios en los serogrupos en el Cono Sur. Rev. Chil. Inf. 2012; 29: S87.

  40. American Academic of Pediatrics. Infecciones meningocócicas. En: Pickering LK, Baker CJ, Kimberlin DW, Long MD eds. Red book: Informe 2012 del Comité de Enfermedades infecciosas. Elk Grove Village, IL: American Academy of Pediatrics 2012:500-9.

  41. Granoff DM, Pelton S, Harrison LH. Meningococcal vaccines in: PlotkinSA, Orenstein WA, Offit PA ed. Vaccines 6th ed. Elsevier Saunders. China 2013; 388-418.

  42. Knapp JS, Koumans EH. Neisseria and Branhamella. In: Murray PR, Baron Ej, Jorgensen JH et al ed. Manual of Clinical Microbiology, 9th ed. Washington, DC: ASM Press. 2007; 586-603.

  43. Branham SE. Serological relationships among meningococci. Bacteriol Rev. 1953 Sep; 17(3): 175-88.

  44. Vedros NA. Development of meningococcal serogrups. In Vedros NA. Ed.Evolution of Meningococcal Disease, Boca Raton, FL: CRC Press. 1987; 33-37.

  45. Safadi MAP, Sáenz-Llorens X, Gonzalez-Ayala S, et al. Efforts to control and prevented meningococcal disease in Latin America. The Global Meningococcal Initiative WSPID. 2011.

  46. Safadi MA, Cintra OA. Epidemiology of meningococal disease in Latin America: Current Situation and opportunities for prevention, Neurological Research. 2010; 32(3): 263-264.

  47. López EL, Debbag R. Enfermedad meningocócica: siempre presente. Cambios en los serogrupos en el Cono Sur. Rev Chilena Infectol. 2012; 29(6): 587-94.

  48. SS. Información Epidemiológica de Morbilidad, Anuario 2009, pp.118.6. Dirección General de Epidemiología 2009.

  49. Vigilancia Epidemiológica semana 26-2013. SS (México).

  50. Espinosa LE, Aguilar-Ituarte F, Jiménez-Rojas LV, et al. Prevalence of Neisseria meningitidis carriers in children under five years of age and teenagers in certain populations of Mexico City. Salud Pública de México. 2009 Mar-abr; 51(2): 114-8.

  51. Espinosa de los Monteros LE, Jiménez LV, Villaseñor I, et al. Prevalence of N. meningitidis carriers in two prisons in Mexico during the epidemiological emergency of a meningitid outbreak in Mexico City (2010). 2012.

  52. Centers for Disease Control and Prevention (CDC) Prevention and Control of Meningococcal Disease Recommendations of Advisory Committee on Immunization Practices (ACIP) MMWR 2005; 54(No. RR-7): 1-21.

  53. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedules for Persons Aged 0 through 18 years and adults aged 19 years and older - United States, 2013 MMWR. 2013; 62(Suppl1): 1-19.

  54. Nassif X. Interaction mechanisms of encapsulated meningococci with eucaryotic cells: what does this tell us about the crossing of the blood-brain barrier by Neisseria meningitidis?. CurrOpin Microbiol. 1999 Feb; 2(1): 71-7.

  55. Red Book online update 7-septiembre 2013 (Chapter meningococcal infectious).

  56. MMWR. 2013; 62: 2.

  57. Harrison O.B. y Cols Description and Nomenclature of Neisseria meningitidis Capsule locus. Emerg. Infec. Dis. 2013: 19(4); 566.




2020     |     www.medigraphic.com